On Building A Better R&D Machine, Part 2: Pfizer’s R&D Chief Mikael Dolsten Talks Partnering Strategy And Accessing Innovation

We sat down with Pfizer Inc.’s Worldwide President of R&D Mikael Dolsten on Feb. 13 at the BIO CEO conference in New York to drill down into some of the subjects covered in his conference fireside chat earlier that morning. Dolsten leads Pfizer’s small and large molecule R&D across all therapeutic areas as well as vaccines. He also co-chairs the company's Portfolio Strategy and Investment (PSI) Committee, which governs major pipeline investments and strategic R&D priorities. He joined Pfizer in 2009 from Wyeth where he was president of Wyeth Research.

Pfizer’s focus in deal making is on transactions that make economic sense and – particularly for assets requiring a significant investment in clinical development – are collaborative and risk-sharing in...